Source : https://pubmed.ncbi.nlm.nih.gov/40356916/
Clinically, anti-AChR/LRP4 antibodies double-seropositive MG is rare, often onset after middle age, more common in females, frequently involving bulbar muscles, severe symptoms, poor prognosis, and unrelated to thymoma. Muscle atrophy...
Rare case of double-seropositive AChR/LRP4 antibody myasthenia gravis with muscle atrophy; reveals severe symptoms, bulbar involvement, and poor prognosis, expanding understanding of atypical gMG variants.
Source : https://pubmed.ncbi.nlm.nih.gov/40360002/
Comorbid autoimmune disorders affect approximately 0.2% of the population. A second autoimmune disease occurs in up to 15% of myasthenia gravis (MG) patients.To evaluate the association between MG and inflammatory...
Myasthenia gravis is significantly more prevalent in IBD patients, including muscle-specific kinase-positive cases. Findings reveal diagnostic masking by immunotherapy and frequent comorbidities with other autoimmune and neuropathic conditions.
Source : https://pubmed.ncbi.nlm.nih.gov/40321274/
Accurate prediction of patient outcomes in clinical trials is crucial for timely assessment of treatment efficacy. This study introduces a novel approach to predict patient response by constructing temporal trajectories...
This study introduces a method to predict myasthenia gravis patient outcomes in clinical trials by analyzing longitudinal data, identifying response patterns, and linking treatment success with factors like age and smoking status.
Source : https://pubmed.ncbi.nlm.nih.gov/40322556/
Background: The relationship between autoimmune diseases (AIDs) and cancer is unclear and this study aimed to investigate the relationship between AIDs and cancer at the genetic level using Mendelian randomization...
This study uses Mendelian Randomization to investigate genetic associations between autoimmune diseases (AIDs) and cancer, identifying significant links between conditions like myasthenia gravis, multiple sclerosis, and various cancers.
In CHAMPION‑MG, ravulizumab delivered clinically meaningful MG‑ADL and QMG improvements within 1 week and sustained them through 26 weeks—with a placebo‑like AE profile. Dosing every 8 weeks could de‑stress infusion chairs and patients alike.
Would a q8‑week schedule reshape your steroid‑sparing algorithm?